Literature DB >> 17214899

Psychiatric disorder criteria and their application to research in different racial groups.

Nancy C P Low, John Hardy.   

Abstract

BACKGROUND: The advent of standardized classification and assessment of psychiatric disorders, and considerable joint efforts among many countries has led to the reporting of international rates of psychiatric disorders, and inevitably, their comparison between different racial groups.
RESULTS: In neurologic diseases with defined genetic etiologies, the same genetic cause has different phenotypes in different racial groups.
CONCLUSION: We suggest that genetic differences between races mean that diagnostic criteria refined in one racial group, may not be directly and simply applicable to other racial groups and thus more effort needs to be expended on defining diseases in other groups. Cross-racial confounds (in addition to cultural confounds) make the interpretation of rates in different groups even more hazardous than seems to have been appreciated.

Entities:  

Mesh:

Year:  2007        PMID: 17214899      PMCID: PMC1784090          DOI: 10.1186/1471-244X-7-1

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


Text

The DSM [1] and ICD [2] psychiatric disorder criteria represent the extracted wisdom of predominantly Caucasian psychiatrists treating predominantly Caucasian patients. They have been useful clinically for the important pragmatic reasons that, within this group, they facilitate efficient communication between physicians about patients, reporting on morbidity and mortality statistics, attempts at common treatments, and billing of third party payers. However, they have little biological validity and there is no evidence that they reflect etiology. They have opened the door to many pharmacologic and behavioral intervention trials [3-6] and etiologic investigations that have, in general, been disappointing. However, these disordered symptom clusters (often comprised of variations in normal human feelings) reflect complexity that we have not been able to fully appreciate and this is in part due to our obscured vision of them through the lens of DSM/ICD classification. Despite this derivation, cross-racial comparisons of disorder rates are a frequent topic of investigation and interpretation [7,8]. While most researchers would accept that it is challenging to compare diagnostic rates of psychiatric disorders across cultures [9] they have not considered the possibility that clinical manifestations of the same etiology may be different in people of different genetic backgrounds (that is, their race). While clinical neurological diagnoses are essentially made by the same operational process of clinical consensus, these clinical diagnoses have traditionally been validated through neuropathological examination. In many cases, this biological validation can be made since the genetic etiologies of many neurological diseases are now known. In the limited number of times this biological validation has been compared retrospectively against the clinical (and pathologic) characterization of neurological disease, it has become clear that the clinical characterization holds up poorly in different racial groups. For example, the phenotypes of both Spinocerebellar Ataxia types 2 and 3 (SCA2 and SCA3) are different in Eastern Asians and Sub-Saharan-Africans respectively from their phenotypes in Caucasians [10-13]. Dentatorubral-Pallidoluysian Atrophy in the Japanese is different from Haw River syndrome in African-Americans despite being caused by the same polyglutamine expansion [14,15]. Presenilin mutations present with Alzheimer's disease with a predominantly early memory change in Caucasians, but seem to present with personality change in those of African descent [16]. These differences in clinical phenotypes are reminiscent of the differences seen in different strains of transgenic mice with the same transgene [17] and should not be surprising to geneticists [18,19]. The process of validation through biological examination is not possible in psychiatric diagnoses (though many attempts are underway in the search for "endophenotypes" or biomarkers); in fact, many psychiatric syndromes are mimicked by known medical disorders, such as, hyper/hypothyroidism, pancreatic cancer, hyperparathyroidism, lyme disease (mood changes, mania, depression); hypo/hyperglycemia, pheochromocytoma (panic), thiamine deficiency, normal pressure hydrocephalus (dementia, cognitive changes), lead poisoning (attention deficit hyperactivity disorder), etc., and a psychiatric diagnosis is only made following their exclusion, as the DSM-IV dictates. Given this precedent, it seems ill advised to interpret any differences in disorder rates between different racial groups as being indicative of different rates of exposures to risk factors. This potential for confounding genetic variability is in addition to the more widely recognized, culturally derived issues inherent in the interpretation of most "risk factors" in psychiatric disorders, such as parenting styles, low socioeconomic status, temperament, or psychological "trauma." Since the diagnostic criteria have been imperfectly tuned to ensure, as far as possible, that everyone with mental illness in a Caucasian population receives a diagnosis (for billing, treatment, etiologic study and needs assessment surveys), it should not be surprising to find that the rates in non-Caucasians would be different. Therefore, even given identical exposures, one should expect lower rates of DSM/ICD categories in non-Caucasians since less people in those groups would fit comfortably a diagnostic category. The limited data available suggest this is generally the case [18]. This does not imply that the burden of mental distress is less in other races, but rather our instruments of assessment and diagnosis are less appropriately applied in such genetically different individuals.

Abbreviations

DSM – Diagnostic and Statistical Manual of Mental Disorders; ICD – International Classification of Diseases.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

JH and NL conceived of the manuscript. JH drafted the initial version and both participated in multiple revisions until the final version.

Pre-publication history

The pre-publication history for this paper can be accessed here:
  15 in total

Review 1.  The place of culture in DSM-IV.

Authors:  J E Mezzich; L J Kirmayer; A Kleinman; H Fabrega; D L Parron; B J Good; K M Lin; S M Manson
Journal:  J Nerv Ment Dis       Date:  1999-08       Impact factor: 2.254

2.  Ethnic differences and disease phenotypes.

Authors:  John Hardy; Andrew Singleton; Katrina Gwinn-Hardy
Journal:  Science       Date:  2003-05-02       Impact factor: 47.728

3.  Creation of a clinical classification. International statistical classification of diseases and related health problems--10th revision, Australian modification (ICD-10-AM).

Authors:  K Innes; J Hooper; M Bramley; P DahDah
Journal:  Health Inf Manag       Date:  1997 Mar-May       Impact factor: 3.185

4.  Specifying race-ethnic differences in risk for psychiatric disorder in a USA national sample.

Authors:  Joshua Breslau; Sergio Aguilar-Gaxiola; Kenneth S Kendler; Maxwell Su; David Williams; Ronald C Kessler
Journal:  Psychol Med       Date:  2005-10-05       Impact factor: 7.723

5.  Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese.

Authors:  K Gwinn-Hardy; J Y Chen; H C Liu; T Y Liu; M Boss; W Seltzer; A Adam; A Singleton; W Koroshetz; C Waters; J Hardy; M Farrer
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

Review 6.  Evidence-based research on the efficacy of psychologic interventions in bipolar disorders: a critical review.

Authors:  Eduard Vieta; Isabella Pacchiarotti; Jan Scott; Jose Sánchez-Moreno; Sylvia Di Marzo; Francesc Colom
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 5.285

7.  Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys.

Authors:  Koen Demyttenaere; Ronny Bruffaerts; Jose Posada-Villa; Isabelle Gasquet; Viviane Kovess; Jean Pierre Lepine; Matthias C Angermeyer; Sebastian Bernert; Giovanni de Girolamo; Pierluigi Morosini; Gabriella Polidori; Takehiko Kikkawa; Norito Kawakami; Yutaka Ono; Tadashi Takeshima; Hidenori Uda; Elie G Karam; John A Fayyad; Aimee N Karam; Zeina N Mneimneh; Maria Elena Medina-Mora; Guilherme Borges; Carmen Lara; Ron de Graaf; Johan Ormel; Oye Gureje; Yucun Shen; Yueqin Huang; Mingyuan Zhang; Jordi Alonso; Josep Maria Haro; Gemma Vilagut; Evelyn J Bromet; Semyon Gluzman; Charles Webb; Ronald C Kessler; Kathleen R Merikangas; James C Anthony; Michael R Von Korff; Philip S Wang; Traolach S Brugha; Sergio Aguilar-Gaxiola; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Alan M Zaslavsky; T Bedirhan Ustun; Somnath Chatterji
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

8.  Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia.

Authors:  Gregory A Rippon; Richard Crook; Matthew Baker; Elizabeth Halvorsen; Steven Chin; Michael Hutton; Henry Houlden; John Hardy; Timothy Lynch
Journal:  Arch Neurol       Date:  2003-06

9.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

10.  The Haw River syndrome: dentatorubropallidoluysian atrophy (DRPLA) in an African-American family.

Authors:  J R Burke; M S Wingfield; K E Lewis; A D Roses; J E Lee; C Hulette; M A Pericak-Vance; J M Vance
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.